The significance of Stanniocalcin 2 in malignancies and mechanisms

References

• Chang AC, Janosi J, Hulsbeek M, et al. A novel human cDNA highly homologous to the fish hormone stanniocalcin. Mol Cell Endocrinol. 1995;112(2):241–247.
   PubMed Web of Science ®Google Scholar
• Topcu TO, Ozdemir F, Kavgaci H, et al. The clinical importance of serum urokinase plasminogen activator receptor and carbonic anhydrase IX levels and the effect of anthracycline-based adjuvant chemotherapy on these biomarkers in breast cancer. J Cancer Res Ther. 2018;14(3):608–613.
   PubMed Web of Science ®Google Scholar
• Ji ZY, Li HF, Lei Y, et al. Phosphatase and tensin homolog protein may be linked to lymph node metastasis and tumor node metastasis staging in nonsmall cell lung cancer. J Cancer Res Ther. 2018;14(Supplement):S138–S44.
   PubMedGoogle Scholar
• Wu J, Lai M, Shao C, et al. STC2 overexpression mediated by HMGA2 is a biomarker for aggressiveness of high-grade serous ovarian cancer. Oncol Rep. 2015;34(3):1494–1502.
   PubMed Web of Science ®Google Scholar
• Law AY, Wong CK. Stanniocalcin-2 promotes epithelial-mesenchymal transition and invasiveness in hypoxic human ovarian cancer cells. Exp Cell Res. 2010;316(20):3425–3434.
   PubMed Web of Science ®Google Scholar
• Law AY, Wong CK. Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia. Exp Cell Res. 2010;316(3):466–476.
   PubMed Web of Science ®Google Scholar
• Hou J, Wang Z, Xu H, et al. Stanniocalicin 2 suppresses breast cancer cell migration and invasion via the PKC/claudin-1-mediated signaling. PLoS One. 2015;10(4):e0122179.
   PubMed Web of Science ®Google Scholar
• Wang Y, Gao Y, Cheng H, et al. Stanniocalcin 2 promotes cell proliferation and cisplatin resistance in cervical cancer. Biochem Biophys Res Commun. 2015;466(3):362–368.
   PubMed Web of Science ®Google Scholar
• Kashyap MK, Pawar HA, Keerthikumar S, et al. Evaluation of protein expression pattern of stanniocalcin 2, insulin-like growth factor-binding protein 7, inhibin beta A and four and a half LIM domains 1 in esophageal squamous cell carcinoma. Cancer Biomark. 2012;12(1):1–9.
   PubMed Web of Science ®Google Scholar
• Wang H, Wu K, Sun Y, et al. STC2 is upregulated in hepatocellular carcinoma and promotes cell proliferation and migration in vitro. BMB Rep. 2012;45(11):629–634.
   PubMed Web of Science ®Google Scholar
• Chang AC, Jellinek DA, Reddel RR. Mammalian stanniocalcins and cancer. Endocr Relat Cancer. 2003;10(3):359–373.
   PubMed Web of Science ®Google Scholar
• Lafeber FP, Perry SF. Experimental hypercalcemia induces hypocalcin release and inhibits branchial Ca2+ influx in freshwater trout. Gen Comp Endocrinol. 1988;72(1):136–143.
   PubMed Web of Science ®Google Scholar
• Lu M, Wagner GF, Renfro JL. Stanniocalcin stimulates phosphate reabsorption by flounder renal proximal tubule in primary culture. Am J Physiol. 1994;267(5 Pt 2):R1356–62.
   PubMedGoogle Scholar
• Chang AC, Reddel RR. Identification of a second stanniocalcin cDNA in mouse and human: stanniocalcin 2. Mol Cell Endocrinol. 1998;141(1–2):95–99.
   PubMed Web of Science ®Google Scholar
• DiMattia GE, Varghese R, Wagner GF. Molecular cloning and characterization of stanniocalcin-related protein. Mol Cell Endocrinol. 1998;146(1–2):137–140.
   PubMed Web of Science ®Google Scholar
• Ishibashi K, Miyamoto K, Taketani Y, et al. Molecular cloning of a second human stanniocalcin homologue (STC2). Biochem Biophys Res Commun. 1998;250(2):252–258.
   PubMed Web of Science ®Google Scholar
• Moore EE, Kuestner RE, Conklin DC, et al. Stanniocalcin 2: characterization of the protein and its localization to human pancreatic alpha cells. Horm Metab Res. 1999;31(7):406–414.
   PubMed Web of Science ®Google Scholar
• White KE, Biber J, Murer H, et al. Chromosomal localization of two human genes involved in phosphate homeostasis: the type IIb sodium-phosphate cotransporter and stanniocalcin-2. Somat Cell Mol Genet. 1998;24(6):357–362.
   PubMedGoogle Scholar
• Kita Y, Mimori K, Iwatsuki M, et al. STC2: a predictive marker for lymph node metastasis in esophageal squamous-cell carcinoma. Ann Surg Oncol. 2011;18(1):261–272.
   PubMed Web of Science ®Google Scholar
• Jellinek DA, Chang AC, Larsen MR, et al. Stanniocalcin 1 and 2 are secreted as phosphoproteins from human fibrosarcoma cells. Biochem J. 2000;350(Pt 2):453–461.
   PubMedGoogle Scholar
• Gagliardi AD, Kuo EY, Raulic S, et al. Human stanniocalcin-2 exhibits potent growth-suppressive properties in transgenic mice independently of growth hormone and IGFs. Am J Physiol Endocrinol Metab. 2005;288(1):E92–105.
   PubMed Web of Science ®Google Scholar
• Takei Y, Yamamoto H, Masuda M, et al. Stanniocalcin 2 is positively and negatively controlled by 1,25(OH)(2)D(3) and PTH in renal proximal tubular cells. J Mol Endocrinol. 2009;42(3):261–268.
   PubMed Web of Science ®Google Scholar
• Ichikawa T, Horie-Inoue K, Ikeda K, et al. Vitamin K2 induces phosphorylation of protein kinase A and expression of novel target genes in osteoblastic cells. J Mol Endocrinol. 2007;39(4):239–247.
   PubMed Web of Science ®Google Scholar
• Kristensen LP, Chen L, Nielsen MO, et al. Temporal profiling and pulsed SILAC labeling identify novel secreted proteins during ex vivo osteoblast differentiation of human stromal stem cells. Mol Cell Proteomics. 2012;11(10):989–1007.
   PubMed Web of Science ®Google Scholar
• Zhou J, Li Y, Yang L, et al. Stanniocalcin 2 improved osteoblast differentiation via phosphorylation of ERK. Mol Med Rep. 2016;14(6):5653–5659.
   PubMed Web of Science ®Google Scholar
• Jiang J, Westberg JA, Andersson LC. Stanniocalcin 2, forms a complex with heme oxygenase 1, binds hemin and is a heat shock protein. Biochem Biophys Res Commun. 2012;421(2):274–279.
   PubMed Web of Science ®Google Scholar
• Coulson-Gilmer C, Humphries MP, Sundara Rajan S, et al. Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancer. J Pathol Clin Res. 2018;4(4):241–249.
   PubMedGoogle Scholar
• Jansen MP, Sas L, Sieuwerts AM, et al. Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease. Mol Oncol. 2015;9(6):1218–1233.
   PubMed Web of Science ®Google Scholar
• Esseghir S, Kennedy A, Seedhar P, et al. Identification of NTN4, TRA1, and STC2 as prognostic markers in breast cancer in a screen for signal sequence encoding proteins. Clin Cancer Res. 2007;13(11):3164–3173.
   PubMed Web of Science ®Google Scholar
• Jiang ST, Wang HQ, Yang TC, et al. Expression of Stanniocalcin 2 in breast cancer and its clinical significance. Curr Med Sci. 2019;39(6):978–983.
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Martinez SR, Goto Y, et al. Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes. Clin Cancer Res. 2007;13(14):4105–4110.
   PubMed Web of Science ®Google Scholar
• Buckanovich RJ, Sasaroli D, O’Brien-Jenkins A, et al. Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol. 2007;25(7):852–861.
   PubMed Web of Science ®Google Scholar
• Law AY, Lai KP, Ip CK, et al. Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells. Exp Cell Res. 2008;314(8):1823–1830.
   PubMed Web of Science ®Google Scholar
• Ferreira do Carmo A, Dourado MR, Ervolino de Oliveira C, et al. Stanniocalcin 2 contributes to aggressiveness and is a prognostic marker for oral squamous cell carcinoma. Exp Cell Res. 2020;393(2):112092.
   PubMed Web of Science ®Google Scholar
• Yokobori T, Mimori K, Ishii H, et al. Clinical significance of stanniocalcin 2 as a prognostic marker in gastric cancer. Ann Surg Oncol. 2010;17(10):2601–2607.
   PubMed Web of Science ®Google Scholar
• Arigami T, Uenosono Y, Ishigami S, et al. Clinical significance of stanniocalcin 2 expression as a predictor of tumor progression in gastric cancer. Oncol Rep. 2013;30(6):2838–2844.
   PubMed Web of Science ®Google Scholar
• Ke J, Zhang BH, Li YY, et al. MiR-1-3p suppresses cell proliferation and invasion and targets STC2 in gastric cancer. Eur Rev Med Pharmacol Sci. 2019;23(20):8870–8877.
   PubMed Web of Science ®Google Scholar
• Wang YY, Li L, Zhao ZS, et al. Clinical utility of measuring expression levels of KAP1, TIMP1 and STC2 in peripheral blood of patients with gastric cancer. World J Surg Oncol. 2013;11:81.
   PubMed Web of Science ®Google Scholar
• Fang Z, Tian Z, Luo K, et al. Clinical significance of stanniocalcin expression in tissue and serum of gastric cancer patients. Chin J Cancer Res. 2014;26(5):602–610.
   PubMed Web of Science ®Google Scholar
• Hashemzadeh S, Arabzadeh AA, Estiar MA, et al. Clinical utility of measuring expression levels of Stanniocalcin 2 in patients with colorectal cancer. Med Oncol. 2014;31(10):237.
   PubMed Web of Science ®Google Scholar
• Ieta K, Tanaka F, Yokobori T, et al. Clinicopathological significance of stanniocalcin 2 gene expression in colorectal cancer. Int J Cancer. 2009;125(4):926–931.
   PubMed Web of Science ®Google Scholar
• Chen B, Zeng X, He Y, et al. STC2 promotes the epithelial-mesenchymal transition of colorectal cancer cells through AKT-ERK signaling pathways. Oncotarget. 2016;7(44):71400–71416.
   PubMedGoogle Scholar
• Zhang C, Chen S, Ma X, et al. Upregulation of STC2 in colorectal cancer and its clinicopathological significance. Onco Targets Ther. 2019;12:1249–1258.
   PubMed Web of Science ®Google Scholar
• Li Q, Zhou X, Fang Z, et al. Effect of STC2 gene silencing on colorectal cancer cells. Mol Med Rep. 2019;20(2):977–984.
   PubMed Web of Science ®Google Scholar
• Li JB, Liu ZX, Zhang R, et al. Sp1 contributes to overexpression of stanniocalcin 2 through regulation of promoter activity in colon adenocarcinoma. World J Gastroenterol. 2019;25(22):2776–2787.
   PubMed Web of Science ®Google Scholar
• Sunita BS, Sen A, Suhag V. To evaluate immunoreactivity of cyclooxygenase-2 in cases of endometrial carcinoma and correlate it with expression of p53 and vascular endothelial growth factor. J Cancer Res Ther. 2018;14(6):1366–1372.
   PubMed Web of Science ®Google Scholar
• Miyazaki S, Kikuchi H, Iino I, et al. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts. Int J Cancer. 2014;135(2):295–307.
   PubMed Web of Science ®Google Scholar
• Yuan Q, Zhan L, Zhang -L-L, et al. Stanniocalcin 2 induces oxaliplatin resistance in colorectal cancer cells by upregulating P-glycoprotein. Can J Physiol Pharmacol. 2016;94(9):929–935.
   PubMed Web of Science ®Google Scholar
• Wu F, Li TY, Su SC, et al. STC2 as a novel mediator for Mus81-dependent proliferation and survival in hepatocellular carcinoma. Cancer Lett. 2017;388:177–186.
   PubMed Web of Science ®Google Scholar
• Guo GX, Li QY, Ma WL, et al. MicroRNA-485-5p suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting stanniocalcin 2. Int J Clin Exp Pathol. 2015;8(10):12292–12299.
   PubMed Web of Science ®Google Scholar
• Zhang C, Guan Z, Peng J. [The correlation between stanniocalcin 2 expression and prognosis in laryngeal squamous cell cancer]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2015;29(2):102–107.
   PubMedGoogle Scholar
• Zhou H, Li YY, Zhang WQ, et al. Expression of stanniocalcin-1 and stanniocalcin-2 in laryngeal squamous cell carcinoma and correlations with clinical and pathological parameters. PLoS One. 2014;9(4):e95466.
   PubMed Web of Science ®Google Scholar
• Lin S, Guo Q, Wen J, et al. Survival analyses correlate stanniocalcin 2 overexpression to poor prognosis of nasopharyngeal carcinomas. J Exp Clin Cancer Res. 2014;33:26.
   PubMed Web of Science ®Google Scholar
• He H, Qie S, Guo Q, et al. Stanniocalcin 2 (STC2) expression promotes post-radiation survival, migration and invasion of nasopharyngeal carcinoma cells. Cancer Manag Res. 2019;11:6411–6424.
   PubMed Web of Science ®Google Scholar
• Na SS, Aldonza MB, Sung HJ, et al. Stanniocalcin-2 (STC2): a potential lung cancer biomarker promotes lung cancer metastasis and progression. Biochim Biophys Acta. 2015;1854(6):668–676.
   PubMed Web of Science ®Google Scholar
• Meyer HA, Tolle A, Jung M, et al. Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. Eur Urol. 2009;55(3):669–678.
   PubMed Web of Science ®Google Scholar
• Tamura K, Furihata M, Chung SY, et al. Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer. Cancer Sci. 2009;100(5):914–919.
   PubMed Web of Science ®Google Scholar
• Yoon JH, Kim J, Kim KL, et al. Proteomic analysis of hypoxia-induced U373MG glioma secretome reveals novel hypoxia-dependent migration factors. Proteomics. 2014;14(12):1494–1502.
   PubMed Web of Science ®Google Scholar
• Volland S, Kugler W, Schweigerer L, et al. Stanniocalcin 2 promotes invasion and is associated with metastatic stages in neuroblastoma. Int J Cancer. 2009;125(9):2049–2057.
   PubMed Web of Science ®Google Scholar
• Yang S, Ji Q, Chang B, et al. STC2 promotes head and neck squamous cell carcinoma metastasis through modulating the PI3K/AKT/Snail signaling. Oncotarget. 2017;8(4):5976–5991.
   PubMedGoogle Scholar
• Li T, Qin Y, Zhen Z, et al. Long non-coding RNA HOTAIR/microRNA-206 sponge regulates STC2 and further influences cell biological functions in head and neck squamous cell carcinoma. Cell Prolif. 2019;52(5):e12651.
   PubMed Web of Science ®Google Scholar